본문으로 건너뛰기
ProhibitedBinding ruleKRNo English translation공식 출처 가져오기 확인됨

타크로리무스(tacrolimus), 그 염류 및유도체

Listed by the Korean MFDS as a substance that may not be used in cosmetics.

규제 판단 및 전체 조건

상태
Prohibited
법적 역할
Binding rule
규제 요약
Listed by the Korean MFDS as a substance that may not be used in cosmetics.
조건 및 제한 사항

타크로리무스

물질 정체

공식 출처상의 명칭
타크로리무스(tacrolimus), 그 염류 및유도체
CAS
104987-11-3
EC
Not supplied in this source row
정체 매핑
standalone:official_korean_name

이 정체의 시장 간 요약

현재 이 사이트에 있는 정확히 연결된 기록입니다. 시장이 없는 것은 가져온 정확한 일치 항목이 없다는 뜻이며, 해당 물질의 사용이 허용된다는 뜻이 아닙니다.

시장 데이터세트 1개

South Korea

현재 기록
Prohibited

연결된 기록 1건 · 특정 조건이 있는 기록 1건

보조 기록 열기
CAS 104987-11-3의 PubChem 2D 화학 구조
CAS 104987-11-3PubChem CID 445643

CAS 104987-11-3의 검증된 화학 정보

Tacrolimus

Tacrolimus is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after transplantation. Tacrolimus therapy can be associated with mild serum enzyme elevations, and it has been linked to rare instances of clinically apparent cholestatic liver injury. — LiverTox

IUPAC 명칭
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
분자식
C44H69NO12
분자량
804.0 g/mol
정확한 질량
803.48197664 Da
단일 동위원소 질량
803.48197664 Da
XLogP3
2.7
위상 극성 표면적
178.0 Ų
분자 복잡도
1480.0
형식 전하
0
수소 결합 공여체
3
수소 결합 수용체
12
회전 가능 결합
7
중원자
57
공유결합 단위
1

PubChem에 보고된 명칭 및 동의어

FujimycinPrografTsukubaenolideAdvagrafModigrafProtopicTacrolimus anhydrousFK506
보고된 명칭 16개 더 보기
FK 506ProtopyAnhydrous TacrolimusTACROLIMUS MONOHYDRATEEnvarsusAvagrafFR-900506PrograftTacrolimus, anhydrousAstagraf XLEnvarsus XRTacrolimus (anhydrous)AdoportCapexionHecoriaPerixis
외부 데이터베이스 식별자
고급 구조 통계
정의된 원자 입체중심
14
정의되지 않은 원자 입체중심
0
정의된 결합 입체중심
2
정의되지 않은 결합 입체중심
0
3D 형태이성질체
0
기계 판독 가능한 구조 식별자
SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
InChI
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
InChIKey
QJJXYPPXXYFBGM-LFZNUXCKSA-N

추가 과학 데이터베이스의 근거

EMBL-EBI ChEBI
식별자 정확히 일치CHEBI:61049

tacrolimus (anhydrous)

A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.

처방
C44H69NO12
평균 질량
804.031 g/mol
단일 동위원소 질량
803.48198 Da
형식 전하
0
  • macrolide lactam — is a (CHEBI:145565)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • macrolide lactam — is a (CHEBI:145565)
추가 선별 명칭
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadec8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN(-)-FK 506FK 506FK506tacrolimusTacrolimustacrolimus anhydrous
이 출처의 상호 참조
  • CAS: 104987-11-3 — KEGG COMPOUND
  • CAS: 104987-11-3 — ChemIDplus
  • CAS: 104987-11-3 — KEGG DRUG
  • REGISTRY_NUMBER: 3647477 — Reaxys
  • REGISTRY_NUMBER: 8821611 — Reaxys
  • MANUAL_X_REF: C01375 — KEGG COMPOUND
  • MANUAL_X_REF: D08556 — KEGG DRUG
  • MANUAL_X_REF: DB00864 — DrugBank
  • MANUAL_X_REF: EP184162 — Patent
  • MANUAL_X_REF: FK5 — PDBeChem
  • MANUAL_X_REF: LMPK04000003 — LIPID MAPS
  • MANUAL_X_REF: US5665727 — Patent

매핑 기준: Exact CAS cross-reference in the ChEBI compound record. 출처 업데이트: 2019-12-03. 가져온 시각: 2026-08-31. 출처 기록 열기

NIH PubChem PUG-View
식별자 정확히 일치445643

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Њ±10%; in adults liver transplant patients is 22Њ±6%; in healthy subjects is 18Њ±5%. The absolute bioavailability in pediatric liver transplant patients was 31Њ±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition. 출처: Toxin and Toxin Target Database (T3DB)
  • Signal: Danger 출처: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (92.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (91.5%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 출처: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement) 출처: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 82 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 출처: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 출처: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 출처: European Chemicals Agency (ECHA)
  • Signal: Danger 출처: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H301: Toxic if swallowed [Danger Acute toxicity, oral] 출처: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) 출처: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: IDENTIFICATION AND USE: Tacrolimus is white to off-white crystalline powder. It is a calcineurin-inhibitor immunosuppressant available in several preparations. Tacrolimus in both oral capsules and a solution for IV injection is used for prophylaxis of organ rejection in patients receiving liver, kidney or heart transplants. Tacrolimus topical ointment is used as a second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children. HUMAN EXPOSURE AND TOXICITY: While most acute overdosages of tacrolimus at up to 30 times the intended dose have been asymptomatic and all patients recovered with no sequelae, some acute overdosages were followed by adverse reactions including tremors, abnormal renal function, hypertension, and peripheral edema. At therapeutic doses, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin, as well as an increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. While there a 출처: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; Tacrolimus toxicity commonly presents as acute kidney injury. Close monitoring of serum creatinine, glomerular filtration rate, and urine output is necessary for patients on tacrolimus. Toxicity may also present as adverse effects, including tremors, electrolyte disturbances, and headaches. Monitor for neurotoxicity, nephrotoxicity, and hypertension. Investigations may indicate increased serum creatinine. An electrocardiogram should be obtained to rule out QT prolongation.; Management of Overdose; No specific antidote is currently available for tacrolimus toxicity, and the drug is not removed by hemodialysis. Management focuses on supportive care, including symptom monitoring and management. Consultation with the poison control center is recommended for current guidance and treatment recommendations. 출처: StatPearls
  • Toxicity Summary: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. 출처: Toxin and Toxin Target Database (T3DB)
  • Uses: THERAPEUTIC CATEGORY: Immunosupressant; dermatological treatment of atopic eczema 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Immunosuppressive Agents 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >25; Use (kg) in USA (2002): 45; Consumption (g per capita; approx.) in Germany (2009): 0.000305; Consumption (g per capita) in the USA (2002): 0.00016; Calculated removal (%): 6 출처: NORMAN Suspect List Exchange
  • Uses: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis. 출처: Toxin and Toxin Target Database (T3DB)

매핑 기준: Existing checksum-valid CAS to unique PubChem CID match. 가져온 시각: 2026-08-31. 출처 기록 열기

과학적 분류와 유해성 주석은 맥락을 제공할 뿐이며, 위에 표시된 시장별 규제 판단을 대체하지 않습니다.

추가 출처 적용 범위 및 일치 상태
출처결과확인됨
EMBL-EBI ChEBI정확히 일치2026-08-31
NIH PubChem PUG-View정확히 일치2026-08-31

기록된 불일치는 출처를 확인했다는 유용한 근거이며, 해당 물질이 다른 곳에 존재하지 않는다는 주장이 아닙니다.

체크섬이 유효한 CAS 일치를 통해 2026-08-31에 NIH PubChem에서 가져왔습니다. 화학적 특성은 이 페이지의 규제 판단을 대체하지 않습니다.

공식 출처 및 출처 정보

등록된 출처
South Korea MFDS cosmetic ingredient data
출처 참조
화장품 안전기준 등에 관한 규정, 별표 1, record 1-946
출처 기록 ID
1-946
출처 버전
2026-19
출처 언어
Korean
번역 상태
No English translation
시행일
2026-03-18
출처 업데이트
2026-03-18
스냅샷 확인
2026-08-30 04:33 UTC
검증 방법
MFDS JSON appendices 1–2 parse; 1077 prohibited, 243 restricted
SHA-256
056de35b843a5e31f709073f9e79d5e6e18f7c9164eb537bb099b185a37ef7d8

등록된 데이터세트 주석

데이터세트 적용 범위
Ingredient identity and separate restriction/regulation data endpoints
권위 관련 주석
Korean source is canonical; English materials alone are not complete enough for certification

이 기록이 시장 데이터세트에서 차지하는 위치

1320
현재 South Korea 기록
1077
Prohibited(으)로 표시된 기록
1320
이 출처 버전의 기록
1252
CAS 정체가 있는 시장 기록

상태 분포

현재 기록 1320건 중 638건에 조건 텍스트가 있습니다. 조건 필드가 비어 있는 경우 위의 기록 유형에 따라 해석되며, 제한 없는 사용에 대한 주장으로 전환되지 않습니다.

South Korea 시장 맥락

Complete current appendix dataset

적용 범위 버전: MFDS Notice 2026-19, effective 18 March 2026

All rows in official Appendix 1 (prohibited) and Appendix 2 (restricted) of the Safety Standards for Cosmetics.

확인 체크리스트

  1. Match the Korean canonical substance name and identifiers.
  2. Review all Appendix 1 and 2 matches and conditions.
  3. Check functional-cosmetic and positive-list requirements where applicable.
  4. Confirm current MFDS notice, responsible seller and label obligations.

공식 시장 출처

확인 절차 및 기록 완전성

이 결과를 규제 준수 판단에 사용하기 전에

  1. “타크로리무스(tacrolimus), 그 염류 및유도체”와(과) 모든 CAS/EC 식별자가 공급업체 규격서의 물질을 가리키는지 확인하세요.
  2. Match the Korean canonical substance name and identifiers.
  3. Review all Appendix 1 and 2 matches and conditions.
  4. Check functional-cosmetic and positive-list requirements where applicable.
  5. Confirm current MFDS notice, responsible seller and label obligations.
  6. 출처 버전을 기록하고, 제조, 신고 또는 시장 출시 전에 규제 기관을 다시 확인하세요.

이 기록에서 제공되는 필드

  • 공식 물질 명칭제공됨
  • CAS제공됨
  • EC제공되지 않음
  • 별도의 조건 텍스트제공됨
  • 시행일제공됨
  • 스냅샷 해시 및 방법제공됨

이 페이지가 답하는 질문

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

이 기록은 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946, 출처 버전 2026-19을(를) 인용합니다. 공식 출처를 여세요.

아니요. CAS는 정체를 확인하는 데 도움이 되지만, 관할권마다 같은 물질을 다르게 분류할 수 있으며 제품 범위, 한도, 경고 문구 및 경과 기간 날짜를 다르게 적용할 수 있습니다.

안정적인 인용

타크로리무스(tacrolimus), 그 염류 및유도체. 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946. South Korea. Source version 2026-19. CosIng Checker regulatory record: https://cosingchecker.com/ko/regulations/kr/records/1595/

법적 권위로서 규제 기관을 인용하세요. 이 페이지는 구조화된 근거 색인이자 확인 보조 도구이며, 공식 본문이나 전문적인 법률 평가를 대체하지 않습니다.

South Korea의 해석 및 한계

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

법적 역할 해석 방법

The cited row forms part of a binding rule or legally incorporated list for this market.

이 페이지의 근거

  • 기록된 결과: Prohibited
  • 법적 역할: Binding rule
  • 출처 버전: 2026-19
  • 시행일: 2026-03-18

증명하지 않는 것

Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

추가 공신력 있는 물질 조사

이 출처들 중 어느 것도 위의 시장 판단을 번복하지 않습니다.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

출처에서 이 정체 조사

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

출처에서 이 정체 조사

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

출처에서 이 정체 조사

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

출처에서 이 정체 조사

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

출처에서 이 정체 조사

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

출처에서 이 정체 조사

US EPA CompTox CTX APIs

가져오기에 API 키 필요

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

출처에서 이 정체 조사